Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Ability of lymphocytes treated with thymic factor to decrease lung metastasis in tumor-bearing mice

D Cupissol, J L Touraine, B Serrou

|June 1, 1981

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A single-arm multicentre phase II trial of doxorubicin in combination with trabectedin in the first-line treatment for leiomyosarcoma with long-term follow-up and impact of cytoreductive surgery.

ESMO open·2021

Same author

A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2021

Same author

Circulating tumour cells in head and neck cancer.

European annals of otorhinolaryngology, head and neck diseases·2020

Same author

A phase II of gemcitabine combined with pazopanib followed by pazopanib maintenance, as second-line treatment in patients with advanced leiomyosarcomas: A unicancer French Sarcoma Group study (LMS03 study).

European journal of cancer (Oxford, England : 1990)·2019

Same author

[What is the best management for a spermatic cord sarcoma in 2018?]

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2018

Same author

[Reprint of: Treatment of patients with inoperable stage III or stage IV melanoma. Société française de dermatologie].

Bulletin du cancer·2018

Pre-incubation of spleen lymphocytes with thymic extract significantly impaired Lewis-tumor development in mice. This thymic factor enhanced immune defense, reducing tumor weight, volume, and lung metastases.

Area of Science:

Immunology
Oncology
Biochemistry

Background:

Tumorigenesis involves complex interactions between cancer cells and the host immune system.
The spleen and thymus are critical lymphoid organs involved in immune responses.
Thymic extracts have been investigated for their potential immunomodulatory effects.

Purpose of the Study:

To investigate the effect of thymic extract-treated lymphocytes on Lewis-tumor growth in C57BL/6 mice.
To determine if thymic factors can enhance anti-tumor immunity.

Main Methods:

C57BL/6 mice were subcutaneously injected with Lewis-tumor cells and syngeneic spleen lymphocytes.
Spleen lymphocytes were pre-incubated with a thymic extract.
Tumor development, weight, volume, and lung metastases were assessed.

Related Experiment Videos

Adrenal and spleen weights were measured.

Main Results:

Pre-incubation with thymic extract significantly impaired tumor development.
Tumor weight and volume were significantly decreased.
The number and size of lung metastases were markedly reduced.
The typical increase in adrenal and spleen weights in tumor-bearing mice was prevented.

Conclusions:

Lymphocytes incubated with thymic factor preparation can enhance the host's defense against Lewis-tumor.
Thymic extracts hold potential as immunomodulatory agents in cancer therapy.
This study highlights the role of thymic factors in bolstering anti-tumor immune responses.